Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Paraganglioma 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasm Metastasis 1Insulinoma 1Hepatoblastoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Carcinoma 1Carcinoid Tumor 1

Interventions

Octreotide 4Everolimus 4Capecitabine 4Temozolomide 3Leucovorin 3vatalanib 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bortezomib 2Bevacizumab 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1motesanib diphosphate 1cixutumumab 1batifiban 1Thalidomide 1Streptozocin 1Sorafenib 1Salts 1Panobinostat 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glucagonoma × cixutumumab × Endocrine × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡